Literature DB >> 26722198

Diagnosis, Preoperative Evaluation, and Assessment of Resectability of Pancreatic and Periampullary Cancer.

Ashish Verma1, Sunit Shukla2, Nimisha Verma3.   

Abstract

Periampullary region encircles a radius of 2 cm around the ampulla of Vater; accordingly, four distinct neoplasias with overlapping imaging features originate in the region. Each of these lesions has a different long-term prognosis; hence, imaging evaluation to characterize the lesion is important. Further certain specific features pertaining to the vascular invasion and systemic spread may decide about the treatment as well as surgical approach. An understanding of the advances in imaging and image processing technology as well as in the methods of image acquisition, for the purpose, is quite relevant towards etching out a rational pre-treatment evaluation protocol. Further, an evidence-based decision as to the choice of optimum modality for answering specific clinical question is of prime importance in achieving a reasonable post-treatment outcome. Pancreatic adenocarcinoma is the fourth most common cancer and a malignancy with one of the least 5-year survival rates (ranging from 6.8 to 15 % depending on peripancreatic extensions, dropping to 1.8 % for metastatic disease). A survival rate of 15-27 % can be achieved if the lesion is resectable but unfortunately, only 10-15 % of patients are eligible for resection. Cystic tumors of pancreas are a rarer variety of pancreatic neoplasia (5-15 % of pancreatic cysts and 1 % of all pancreatic cancers) which have a much better outcome and chances of resection. Being mostly incidentalomas, a timely differentiation of this lesion from the much more common pseudocyst (which would mandate a medical management and a different surgical protocol) is the key for curability. Lastly, the neuroendocrine tumors of pancreas are equally rare (1 % of all pancreatic tumors), but importantly due to associated clinical syndromes and their capability to metastasize early in the course of disease, a timely detection may hence be the key for successful treatment of these lesions. Imaging plays a vital role in the initial detection and characterization as well as in determination of resectability of each of these pancreatic neoplasias. Further, the differentiation of pancreatic head tumors from other periampullary neoplasias is important; the fact that most recurrences are as a result of surgical intervention in an otherwise inoperable disease while most treatment failures are due to improper characterization of the lesion is notable.

Entities:  

Keywords:  Pancreatic cancer; Periampullary cancer; Preoperative evaluation; Resectability

Year:  2015        PMID: 26722198      PMCID: PMC4689701          DOI: 10.1007/s12262-015-1370-0

Source DB:  PubMed          Journal:  Indian J Surg        ISSN: 0973-9793            Impact factor:   0.656


  30 in total

Review 1.  Pancreatic cancer: basic and clinical aspects.

Authors:  Günter Schneider; Jens T Siveke; Florian Eckel; Roland M Schmid
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

Review 2.  Celiac plexus neurolysis in the management of unresectable pancreatic cancer: when and how?

Authors:  Jonathan M Wyse; Yen-I Chen; Anand V Sahai
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

3.  Macrocystic neoplasms of the pancreas: CT differentiation of serous oligocystic adenoma from mucinous cystadenoma and intraductal papillary mucinous tumor.

Authors:  Sang Youn Kim; Jeong Min Lee; Se Hyung Kim; Kyung-Sook Shin; Young Jun Kim; Su Kyung An; Chang Jin Han; Joon Koo Han; Byung Ihn Choi
Journal:  AJR Am J Roentgenol       Date:  2006-11       Impact factor: 3.959

4.  Value of three-dimensional reconstructions in pancreatic carcinoma using multidetector CT: initial results.

Authors:  Miriam Klauss; Max Schöbinger; Ivo Wolf; Jens Werner; Hans-Peter Meinzer; Hans-Ulrich Kauczor; Lars Grenacher
Journal:  World J Gastroenterol       Date:  2009-12-14       Impact factor: 5.742

Review 5.  Cystic pancreatic lesions: a simple imaging-based classification system for guiding management.

Authors:  Dushyant V Sahani; Rajgopal Kadavigere; Anuradha Saokar; Carlos Fernandez-del Castillo; William R Brugge; Peter F Hahn
Journal:  Radiographics       Date:  2005 Nov-Dec       Impact factor: 5.333

6.  MR cholangiopancreatographic differentiation of benign and malignant intraductal mucin-producing tumors of the pancreas.

Authors:  H Irie; H Honda; H Aibe; T Kuroiwa; K Yoshimitsu; K Shinozaki; K Yamaguchi; M Shimada; K Masuda
Journal:  AJR Am J Roentgenol       Date:  2000-05       Impact factor: 3.959

7.  Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes.

Authors:  Brendan C Visser; Yifei Ma; Yulia Zak; George A Poultsides; Jeffrey A Norton; Kim F Rhoads
Journal:  HPB (Oxford)       Date:  2012-06-12       Impact factor: 3.647

Review 8.  State-of-the-art magnetic resonance imaging of pancreatic cancer.

Authors:  Wolfgang Schima; Ahmed Ba-Ssalamah; Peter Goetzinger; Martina Scharitzer; Claus Koelblinger
Journal:  Top Magn Reson Imaging       Date:  2007-12

9.  Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms.

Authors:  G M Fuhrman; C Charnsangavej; J L Abbruzzese; K R Cleary; R G Martin; C J Fenoglio; D B Evans
Journal:  Am J Surg       Date:  1994-01       Impact factor: 2.565

Review 10.  Pancreatic tumors: emphasis on CT findings and pathologic classification.

Authors:  Hee-Woo Cho; Jin-Young Choi; Myeong-Jin Kim; Mi-Suk Park; Joon Seok Lim; Yong Eun Chung; Ki Whang Kim
Journal:  Korean J Radiol       Date:  2011-09-27       Impact factor: 3.500

View more
  1 in total

1.  Combining endoscopic ultrasound and tumor markers improves the diagnostic yield on the etiology of common bile duct dilation secondary to periampullary pathologies.

Authors:  Han Ding; Pinghong Zhou; Meidong Xu; Weifeng Chen; Quanlin Li; Tao Chen; Mingyan Cai; Tianyin Chen; Jingjing Lian; Yiqun Zhang
Journal:  Ann Transl Med       Date:  2019-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.